We are on the cusp of turning the tide against dementia — which makes this an especially bad time to pull back on research.” ...

Kraft Heinz will be pulling artificial dyes from its U.S. products starting in 2027 and will no longer roll out new products ...

The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions ...

The Medicare pay bump for doctors that was part of the House version of Republicans’ tax bill was dropped in the Senate’s ...

Historically, ACIP has been one of the most transparent federal committees, they wrote, with rigorous reporting on conflicts ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech ...

Humana leaders asserted at the company’s investor day Monday that there’s still money to be made on Medicare Advantage ...

A federal judge ruled that some of the grant terminations by the National Institutes of Health on DEI grounds are “void and ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

China is a one of the most important regions for the booming obesity market, thanks to government incentives and changing ...

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.